temozolomide
not tagged
[]
in our first #asco22 presentation kiyatec presents new data: 3d predict glioma prospectively predicted patient response to standard of care temozolomide (tmz), regardless of mgmt methylation status. central nervous system tumors
sunday june 5 8:00 11:00am abstract id 2031 
Kiyatec is disrupting cancer care by accurately predicting patient-specific response and non-response to therapeutics before treatment begins